Full Press Release Details
Nutriband Inc.'s Abuse Deterrent Transdermal Technology
Patent Granted by European Patent Office
ORLANDO, Fla., March 26, 2019 - Nutriband Inc.
(OTCQB: NTRB), a Nevada corporation (the "Company"), announced today that the European Patent Office has granted full
patent protection for European Patent Application EP15740893.1 entitled, "Abuse and Misuse Deterrent Transdermal System"
submitted by its subsidiary, 4P Therapeutics. The patent relates to the Company's proprietary abuse deterrent transdermal
technology, utilized in the fentanyl transdermal system which is being developed at 4P Therapeutics
to combat the opioid epidemic.
About Nutriband Inc.
The Company is primarily
engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is its abuse
deterrent fentanyl transdermal system which the Company is developing to provide clinicians and patients with an extended-release
transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy combined with properties
designed to help combat the opioid crisis by deterring the abuse and misuse of fentanyl patches.
The Company's website
is www.nutriband.com and 4P's website is www.4PTherapeutics.com. Any material
contained in or derived from the Company's or 4P's websites or any other website is not part of this press release.
About Our Forward-Looking Statements
Certain statements contained in this press release,
including, without limitation, statements containing the words "believes," "anticipates,"
"expects" and words of similar import, constitute "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks
and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking
statements as a result of a number of factors, including those including the Company's ability to develop its proposed
abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its
abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical
testing, its ability obtain Federal Food and Drug Administration approval to market any product it may develop in the United
States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in
Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its
ability to attract and retain key personnel; changes in the Company's business strategy or development plans;
competition; business disruptions; adverse publicity and international, national and local general economic and market
conditions and risks generally associated with an undercapitalized development stage company that does not have a product
that can be marketed and the risks contained under "Risk Factors" and "Management's Discussion and
Analysis of Financial Condition and Results of Operations" in the Company's Form 10-K for the year ended
January 31, 2018 and under "Management's Discussion and Analysis of Financial Conditions and Results of
Operations" in the Company's Form 10-Q for the nine months ended October 31, 2018, and the Company's other
filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to
revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date
For more information, contact: